华兰生物
(002007)
| 流通市值：203.46亿 | | | 总市值：236.06亿 |
| 流通股本：15.74亿 | | | 总股本：18.26亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 1,566,637,468.5 | 762,111,441.69 | 4,595,017,702.01 | 3,378,886,377.05 |
| 营业总成本 | 1,241,495,278.17 | 545,394,537.65 | 3,373,662,053.19 | 2,486,370,142.96 |
| 其他经营收益 | | | | |
| 营业利润 | 491,398,425.06 | 298,558,400.34 | 1,228,542,093.21 | 1,008,099,521.47 |
| 利润总额 | 473,999,729.26 | 289,500,377.36 | 1,173,348,364.31 | 972,414,239.42 |
| 净利润 | 395,191,400.94 | 242,594,496.21 | 999,992,847.58 | 827,700,992.33 |
| 每股收益 | | | | |
| 其他综合收益 | - | - | - | - |
| 综合收益总额 | 395,191,400.94 | 242,594,496.21 | 999,992,847.58 | 827,700,992.33 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 8,964,149,959.33 | 8,702,943,388.95 | 8,859,302,029.2 | 10,048,714,890.01 |
| 非流动资产: | | | | |
| 非流动资产合计 | 5,583,578,039.7 | 6,355,834,301.21 | 6,402,964,684.56 | 6,218,654,717.55 |
| 资产总计 | 14,547,727,999.03 | 15,058,777,690.16 | 15,262,266,713.76 | 16,267,369,607.56 |
| 流动负债: | | | | |
| 流动负债合计 | 1,730,122,132.03 | 1,324,172,152.18 | 1,795,309,181.38 | 2,926,029,063.11 |
| 非流动负债: | | | | |
| 非流动负债合计 | 114,472,776.7 | 101,016,767.12 | 75,963,257.73 | 91,743,064.77 |
| 负债合计 | 1,844,594,908.73 | 1,425,188,919.3 | 1,871,272,439.11 | 3,017,772,127.88 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 10,971,600,179.47 | 11,720,324,917.31 | 11,500,605,548.73 | 11,371,869,789.69 |
| 股东权益合计 | 12,703,133,090.3 | 13,633,588,770.86 | 13,390,994,274.65 | 13,249,597,479.68 |
| 负债和股东权益合计 | 14,547,727,999.03 | 15,058,777,690.16 | 15,262,266,713.76 | 16,267,369,607.56 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 2,222,640,050.08 | 882,873,232.12 | 4,517,254,586.11 | 3,106,028,325.26 |
| 经营活动现金流出小计 | 1,879,914,223.6 | 889,262,811.55 | 3,639,298,085.86 | 2,655,399,510.67 |
| 经营活动产生的现金流量净额 | 342,725,826.48 | -6,389,579.43 | 877,956,500.25 | 450,628,814.59 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 5,889,843,685.55 | 2,678,651,192.78 | 12,491,605,975.97 | 9,673,231,639.89 |
| 投资活动现金流出小计 | 5,085,212,547.75 | 2,114,713,943.75 | 11,957,323,173.77 | 8,936,858,346.82 |
| 投资活动产生的现金流量净额 | 804,631,137.8 | 563,937,249.03 | 534,282,802.2 | 736,373,293.07 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 389,103,542.67 | - | 724,942,840.01 | 724,405,900.01 |
| 筹资活动现金流出小计 | 1,359,410,095.1 | 447,000,000 | 2,722,005,980.66 | 1,583,602,566.45 |
| 筹资活动产生的现金流量净额 | -970,306,552.43 | -447,000,000 | -1,997,063,140.65 | -859,196,666.44 |
| 汇率变动对现金及现金等价物的影响 | -142,225.98 | -80,561.38 | 140,062.36 | 175,338.16 |
| 现金及现金等价物净增加额 | 176,908,185.87 | 110,467,108.22 | -584,683,775.84 | 327,980,779.38 |
| 期末现金及现金等价物余额 | 950,484,631.71 | 884,043,554.06 | 773,576,445.84 | 1,686,241,001.06 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | 176,908,185.87 | - | -584,683,775.84 | - |
最新报告期：2026-09-13| 研究机构 | 分析师 | 预测每股收益(元) | 更新日 |
| 2026年 | 2027年 | 2028年 |
| 国投证券 | 胡雨晴 | 0.44 | 0.50 | 0.58 | 2026-09-13 |
| 中信建投 | 汤然,刘若飞,贺菊颖 | 0.44 | 0.52 | 0.61 | 2026-09-09 |
| 华泰证券 | 代雯,唐庆雷,张云逸 | 0.56 | 0.62 | 0.70 | 2026-08-30 |